policymed.com8h
Pioneering Discussions at IISLD 2024: Advancing Treatment for PBC and Alpha-1 Antitrypsin Deficiency
This year's International Symposium on Liver Diseases (IISLD) 2024, held in the San Diego Convention Center, includes two key ...
GlaxoSmithKline (GSK) Gets a Hold from Kepler Capital
In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...
My antidepressants left me with no feeling in my genitals
Daryl Brown, who was prescribed the antidepressant Seroxat in childhood because of his Tourette’s syndrome and OCD, tells ...
Jim Cramer Says GSK plc (GSK) ‘Goes Higher’
We recently published an article titled Jim Cramer on Super Micro Computer and Other Stocks. In this article, we are going to ...
Biohaven: A Complicated Tale
Biohaven has surged driven by promising data from its troriluzole trials for spinocerebellar ataxia and ongoing OCD studies.
MedPage Today21h
Tezepelumab for Severe Asthma Improves the Odds of a Good Night's Sleep
BOSTON -- Patients with severe, uncontrolled asthma had significantly higher odds of improvement in asthma-related sleep ...
Assessing Genmab’s Financial Outlook Amidst Darzalex Market Challenges and Patent Expiry Concerns
TD Cowen analyst Yaron Werber has maintained their neutral stance on GMAB stock, giving a Hold rating yesterday. Yaron Werber’s rating ...
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain
GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...